This brand name is authorized in Brazil, Ecuador.
The drug CIMAHER contains one active pharmaceutical ingredient (API):
1
|
UNII
6NS400BXKH - NIMOTUZUMAB
|
|
Nimotuzumab binds to the extracellular domain of epidermal growth factor receptor (EGFR, HER1, c-ErB1) and inhibits the binding of epidermal growth factor (EGF) and other ligands such as transforming growth factor alfa. Binding of nimotuzumab to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased vascular endothelial growth factor production. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| L01X | Other antineoplastic agents | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| BR | Câmara de Regulação do Mercado de Medicamentos | 508027802156219 |
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 43-MBE-0116 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.